Eli Lilly’s hottest drugs face a quiet new threat
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
The Source
THE STREET
Business
Amazon is selling ChatGPT AI smartglasses that can translate in real time for $18 ahead of Prime Day
THE STREET·1h ago·3 min read
Business
Wall Street’s top analysts just doubled down on 3 stocks
THE STREET·1h ago·3 min read
Business
Micron gets aggressive stock price target from veteran analyst
THE STREET·1h ago·3 min read
Business
The Mag 7 is outdated — here’s where to invest instead
THE STREET·1h ago·3 min read
Related
On this beat
Business
Amazon is selling ChatGPT AI smartglasses that can translate in real time for $18 ahead of Prime Day
THE STREET·1h ago·3 min read
Business
Wall Street’s top analysts just doubled down on 3 stocks
THE STREET·1h ago·3 min read
Business
Micron gets aggressive stock price target from veteran analyst
THE STREET·1h ago·3 min read
Business
The Mag 7 is outdated — here’s where to invest instead
THE STREET·1h ago·3 min read